Abstract
A large number of therapeutic roles have been proposed for σ1 receptors but the involvement of σ1 receptor in non-acute pain had not been well explored up to now. σ1 receptor knock-out mice became available offering us the possibility to study the role of σ1 receptor in nociception, particularly in models where central sensitization processes play a significant role. Given the attractive therapeutic potential, we have developed a chemical program aimed at the discovery of novel and selective σ1 ligands. Herein we discuss the rational basis of this approach and report preliminary pharmacological results of several chemical series and aspects of their structure-activity relationship on σ1 receptor. Functional data in pain models are presented mainly on one series that provide evidence to consider selective σ1 receptor antagonists an innovative and alternative approach for treating neuropathic pain.
Keywords: Neuropathic pain, analgesia, sigma-1 antagonists, sigma-1 knock-out, central sensitization
Central Nervous System Agents in Medicinal Chemistry
Title: Selective Sigma-1 (σ1) Receptor Antagonists: Emerging Target for the Treatment of Neuropathic Pain
Volume: 9 Issue: 3
Author(s): Jose Luis Diaz, Daniel Zamanillo, Jordi Corbera, Jose Manuel Baeyens, Rafael Maldonado, Miquel Angel Pericàs, Jose Miguel Vela and Antoni Torrens
Affiliation:
Keywords: Neuropathic pain, analgesia, sigma-1 antagonists, sigma-1 knock-out, central sensitization
Abstract: A large number of therapeutic roles have been proposed for σ1 receptors but the involvement of σ1 receptor in non-acute pain had not been well explored up to now. σ1 receptor knock-out mice became available offering us the possibility to study the role of σ1 receptor in nociception, particularly in models where central sensitization processes play a significant role. Given the attractive therapeutic potential, we have developed a chemical program aimed at the discovery of novel and selective σ1 ligands. Herein we discuss the rational basis of this approach and report preliminary pharmacological results of several chemical series and aspects of their structure-activity relationship on σ1 receptor. Functional data in pain models are presented mainly on one series that provide evidence to consider selective σ1 receptor antagonists an innovative and alternative approach for treating neuropathic pain.
Export Options
About this article
Cite this article as:
Diaz Luis Jose, Zamanillo Daniel, Corbera Jordi, Baeyens Manuel Jose, Maldonado Rafael, Pericàs Angel Miquel, Vela Miguel Jose and Torrens Antoni, Selective Sigma-1 (σ1) Receptor Antagonists: Emerging Target for the Treatment of Neuropathic Pain, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/1871524910909030172
DOI https://dx.doi.org/10.2174/1871524910909030172 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prediction of Citrullination Sites on the Basis of mRMR Method and SNN
Combinatorial Chemistry & High Throughput Screening Regulation of Gene Expression by TDP-43 and FUS/TLS in Frontotemporal Lobar Degeneration
Current Alzheimer Research Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19
Current Pharmaceutical Design Buprenorphine and Buprenorphine/Naloxone Intoxication in Children – How Strong is the Risk?
Current Drug Abuse Reviews The Neurokinins: Peptidomimetic Ligand Design and Therapeutic Applications
Current Medicinal Chemistry Embryonic Stem Cells or Induced Pluripotent Stem Cells? A DNA Integrity Perspective
Current Gene Therapy How Does the Treadmill Affect Gait in Parkinsons Disease?
Current Aging Science Pathological Gambling: Update on Decision Making and Neuro-functional Studies in Clinical Samples
Current Pharmaceutical Design Phytochemical Informatics and Virtual Screening of Herbs Used in Chinese Medicine
Current Pharmaceutical Design Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β Amyloid-Induced Astrogliosis <i>In Vitro</i>
CNS & Neurological Disorders - Drug Targets Brain Tissue Segmentation from Magnetic Resonance Brain Images Using Histogram Based Swarm Optimization Techniques
Current Medical Imaging Editorial [Hot Topic: Advances in the Pharmacological Approach to Sleep Disorders Executive (Guest Editor: Michelle Cao)]
Current Pharmaceutical Design The Genetic Basis of New Treatment Modalities in Melanoma
Current Drug Targets Vascular Risk Factors and Lesions of Vascular Nature in Magnetic Resonance as Predictors of Progression to Dementia in Patients with Mild Cognitive Impairment
Current Alzheimer Research Synthesis, Characterization and Biological Activities of New Symmetric Bis-1,2,3-Triazoles with Click Chemistry
Medicinal Chemistry Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30
Current Topics in Medicinal Chemistry Promising Targets for Anti-Hepatitis C Virus Agents
Current Medicinal Chemistry Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects
Current Medicinal Chemistry The Immunosuppressive Agent FK506 Prevents Subperineurial Degeneration and Demyelination on Ultrastructural and Functional Analysis
Current Neurovascular Research